Zydelig (Idelalisib) Overview

Zydelig, also known by its generic name Idelalisib, is a targeted therapy used in the treatment of certain types of blood cancers. It is specifically indicated for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma, and small lymphocytic lymphoma who have received at least one prior therapy.

Mechanism of Action

Zydelig works as a selective inhibitor of phosphatidylinositol 3-kinase (PI3K) delta. By blocking this pathway, Zydelig disrupts the survival signals that cancer cells rely on, ultimately leading to their death and reducing tumor growth.

Administration

Zydelig is administered orally in tablet form, typically taken twice daily. It is important for patients to follow their healthcare provider's instructions regarding dosage and schedule.

Common Side Effects

Patients taking Zydelig may experience side effects, including:

• Diarrhea
• Fatigue
• Nausea
• Abdominal pain
• Increased liver enzymes

Serious Risks

Serious side effects can occur, including:

• Severe infections
• Colitis (inflammation of the colon)
• Pneumonitis (inflammation of the lungs)

Patients should report any unusual symptoms to their healthcare provider immediately.

Monitoring and Precautions

Regular monitoring of liver function and blood counts is essential during treatment with Zydelig. Patients should also be screened for infections prior to starting therapy.

Drug Interactions

Patients should inform their healthcare provider about all medications they are taking, as Zydelig may interact with other drugs, impacting their effectiveness or increasing the risk of side effects.

Conclusion

Zydelig represents a significant advancement in the treatment of certain blood cancers, offering a targeted approach that can improve patient outcomes. It is crucial for patients to have open communication with their healthcare team to manage treatment effectively.